Neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center.
Positive Impact of Ataluren on Walking Ability in Duchenne Muscular Dystrophy: Jeffrey M. Statland, MD
At the 2023 AAN Annual Meeting, the neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center talked about the phase 3 study investigating ataluren for Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]
Phase 4 Trial to Test Transition From IVIg to Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy
Bridging Bench to Bedside: Challenges in Advancing Remyelination Therapies
Positive Phase 3 Data for Oral OSA Medication AD109, FDA Clears First Blood Test for Alzheimer Disease, DHE Autoinjector Treatment Approved for Migraine
NeurologyLive® Friday 5 — May 23, 2025